Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2a, Dose-Escalation and Dose-Expansion Study of ZX-101A in Patients With Relapsed/Resistant or Refractory Advanced Hematologic Malignancies

Next Previous
X
Search
Trial Profile

A Phase 1/2a, Dose-Escalation and Dose-Expansion Study of ZX-101A in Patients With Relapsed/Resistant or Refractory Advanced Hematologic Malignancies

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 25 Oct 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ZX-101A (Primary)
  • Indications Chronic lymphocytic leukaemia; Haematological malignancies; Non-Hodgkin's lymphoma
  • Focus Adverse reactions; First in man
  • Sponsors Nanjing Zenshine Pharmaceuticals

    • Most Recent Events

    • 19 Oct 2022 Status changed from recruiting to discontinued.
    • 10 Apr 2021 Trial design, presented at the 112th Annual Meeting of the American Association for Cancer Research
    • 11 Jan 2021 Planned initiation date (estimated date for recruitment of the first subject) changed from 18 Sep 2020 to 29 Jan 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top